Form 8-K

8-K — Enveric Biosciences, Inc.

Accession: 0001493152-26-038385

Filed: 2026-08-14

Period: 2026-08-14

CIK: 0000890821

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000890821

2026-08-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

August

14, 2026

Date

of Report (Date of earliest event reported)

Enveric

Biosciences, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-38286

95-4484725

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

No.)

Enveric

Biosciences, Inc.

245

First Street, Riverview II, 18th Floor

Cambridge,

MA 02142

(Address

of principal executive offices) (Zip code)

Registrant’s

telephone number, including area code: (617) 444-8400

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common stock, par value

$0.01 per share

ENVB

The Nasdaq Stock Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

August 14, 2026, Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for

the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by

reference.

accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, that

is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall

not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended,

or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

Number

Description

99.1

Press Release, dated August 14, 2026 (furnished pursuant to Item 2.02)

104

Cover Page Interactive Data File (formatted as Inline

XBRL)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date: August 14, 2026

ENVERIC BIOSCIENCES, INC.

By:

/s/ Joseph

Tucker

Joseph Tucker

Chief Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Enveric

Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

EB-003

Development Highlights:

● Continued

advancing IND-enabling studies supporting the planned submission of an Investigational New

Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial

● Reported

preclinical data demonstrating that EB-003 consistently exhibited a non-hallucinogenic profile

in a highly sensitive GloSensor™ assay, complementing previously reported BRET assay

findings

● Announced

promising results from preclinical in vitro experiments indicating no photoreactive

potential for EB-003, further derisking its continued development as a potential treatment

of neuropsychiatric disorders

● Initiated

genotoxicity studies to evaluate the potential for EB-003 to interact with DNA and cause

genetic mutations, a critical measure of safety required for IND submission

Corporate

and Business Development Highlights:

● Received

a Notice of Allowance from the USPTO for a patent application covering the Company’s

EVM401 Series of methylone-inspired neuroplastogens

● Secured

U.S. Patent No. 12,605,361 pertaining to the Company’s EVM301 Series of molecules being

developed as potential treatments for mental health disorders

CAMBRIDGE,

Mass., August 14, 2026 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology

company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported

financial results for the second quarter ended June 30, 2026, and provided a comprehensive business update.

CEO

Commentary:

“The

second quarter was highlighted by important progress across the key activities supporting our planned first-in-human clinical trial of

EB-003,” said Joseph Tucker, Ph.D., Chief Executive Officer of Enveric. “Over the past several months, we advanced multiple

IND-enabling studies and generated additional preclinical data that support EB-003’s potential non-hallucinogenic profile. Collectively,

these accomplishments strengthen the scientific foundation of our lead program as we work toward an IND submission for the anticipated

Phase 1 trial.”

Dr.

Tucker continued: “The additional preclinical data announced during the quarter are particularly encouraging because they provide

further validation of our differentiated development strategy. Our previously reported BRET assay findings were reinforced by independent

GloSensor™ assay data, extending the body of evidence supporting EB-003’s differentiated pharmacological profile and its

potential to preserve certain therapeutic benefits associated with neuroplasticity while avoiding the hallucinogenic effects.”

“The

broader neuroplastogenic field also continued to gain momentum during the quarter,” continued Dr. Tucker. “Recent FDA guidance

addressing psychedelic drug development, together with strategic investment by major pharmaceutical companies, reflects increasing recognition

of the therapeutic promise of these mechanisms. We believe these developments further support our long-held strategy of developing next-generation

neuroplastogenic molecules intentionally designed to address many of the limitations associated with first-generation psychedelic-inspired

therapies.”

Dr.

Tucker added: “During the quarter, we also continued to expand Enveric’s intellectual property portfolio. We secured a new

U.S. patent covering methods of treating psychiatric disorders using compounds from our EVM301 Series and subsequently received a Notice

of Allowance for our EVM401 Series of proprietary methylone-inspired neuroplastogens. Together, these achievements reflect our ongoing

commitment to building a broad portfolio of differentiated neuroplastogenic compounds.”

Dr.

Tucker concluded: “As we enter the second half of 2026, our priorities remain clear: complete the remaining IND-enabling activities,

submit our planned IND application, and advance EB-003 into a first-in-human clinical trial. We believe the progress over the past several

months has strengthened both our lead development program and the broader Enveric platform, positioning the Company to continue creating

long-term strategic and shareholder value.”

SECOND

QUARTER 2026 AND RECENT BUSINESS HIGHLIGHTS

Corporate,

Product and Business Development Highlights:

EB-003

Development:

● Reported

highly sensitive GloSensor™ cAMP assay demonstrating that EB-003 consistently exhibited

a differentiated non-hallucinogenic profile.

○ Data

complement previously reported BRET assay findings that support Enveric’s differentiated

approach to developing non-hallucinogenic neuroplastogenic therapeutics.

● Announced

favorable in vitro study results demonstrating that EB-003 did not exhibit photoreactive

potential, supporting its continued development as a potential chronic therapy for patients

with neuropsychiatric disorders.

● Advanced

IND-enabling activities through the initiation of genotoxicity studies, an important component

of the preclinical safety package required to support submission of an IND application.

Intellectual

Property:

● Secured

a new U.S. patent covering methods of treating psychiatric disorders utilizing compounds

from Enveric’s EVM301 Series, further strengthening protection around the Company’s

proprietary tryptamine-derived neuroplastogenic compounds.

● Received

a Notice of Allowance from the USPTO covering the Company’s EVM401 Series of proprietary

methylone-inspired neuroplastogens, expanding Enveric’s growing intellectual property

portfolio.

Financial:

● Closed

a private placement, priced at-the-market under Nasdaq rules, for approximately $5.0 million

in upfront gross proceeds, with the potential for up to approximately $8.9 million in additional

gross proceeds if the associated warrants are exercised in full.

● Raised

an additional approximately $1.5 million from the exercise of warrants.

SECOND

QUARTER FINANCIAL RESULTS

Net

loss attributable to stockholders was $3.0 million for the second quarter ended June 30, 2026, including $0.3 million in net non-cash

expense, with a basic and diluted loss per share of $0.76, as compared to a net loss of $2.5 million, including $0.5 million in net non-cash

expense, with a basic and diluted loss per share of $11.65 for the quarter ended June 30, 2025. The Company had cash-on-hand of $8.3

million as of June 30, 2026. For the quarter ended June 30, 2026, the Company raised gross proceeds of $5.0 million through offerings

and $1.5 million from the exercise of warrants.

About

Enveric Biosciences

Enveric

Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics

that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing

library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without

hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT2A

and 5-HT1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient

convenience.

For

more information, please visit www.enveric.com.

Forward-Looking

Statements

This

press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These

statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking

statements or information, including, without limitation, statements regarding Enveric’s development of EB-003, the Company’s

planned IND submission and planned Phase 1 clinical development of EB-003, the potential implications of the preclinical GloSensor™

cAMP assay results and previously reported BRET assay results, the potential implications of EB-003’s design, receptor activity

and preclinical profile, the potential for EB-003 to be non-hallucinogenic in humans, and Enveric’s beliefs regarding the potential

implications of FDA guidance for psychedelic drugs to EB-003 and its planned clinical development. Generally, forward-looking statements

and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does

not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,”

“estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,”

or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions,

events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding

beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made

by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking

statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND application

to the U.S. Food and Drug Administration; receive clearance to initiate clinical trials; confirm in human clinical trials any non-hallucinogenic,

safety, tolerability, efficacy, durability, dosing, treatment-delivery or outpatient-use profile suggested by preclinical studies; carry

out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical

trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations

for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain

sufficient future funding for product development, clinical development activities, working capital and other operating expenses on commercially

reasonable terms, or at all; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire

and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection;

identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern;

and manage its future growth effectively.

discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings

with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.

Enveric disclaims any intention or obligation to revise or update any forward-looking statements, whether as a result of new information,

future events or otherwise, except as required by law.

Contacts

Investor

Relations

Tiberend

Strategic Advisors, Inc.

David

Irish

(231)

632-0002

dirish@tiberend.com

Media

Relations

Tiberend

Strategic Advisors, Inc.

Casey

McDonald

(646)

577-8520

cmcdonald@tiberend.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (8006 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 14, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 14, 2026

Entity File Number

001-38286

Entity Registrant Name

Enveric

Biosciences, Inc.

Entity Central Index Key

0000890821

Entity Tax Identification Number

95-4484725

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Enveric

Biosciences, Inc.

Entity Address, Address Line Two

245

First Street, Riverview II

Entity Address, Address Line Three

18th Floor

Entity Address, City or Town

Cambridge

Entity Address, State or Province

Entity Address, Postal Zip Code

02142

City Area Code

(617)

Local Phone Number

444-8400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value

$0.01 per share

Trading Symbol

ENVB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration